Table 1. Table summarizing study characteristics.
| Sl number | Study | Study design | Number | Age, years (mean) | Measurement tools | Measurement time |
|---|---|---|---|---|---|---|
| 1 | Li et al. (11) | Prospective, longitudinal | 106 | 61 | QoL: EORTC QLQ-C30; local symptoms (CLSS) | Before starting intravesical Rx; 6 weeks after intravesical treatment |
| 2 | Abáigar-Pedraza et al. (12) | Cross sectional | 180 | – | FACT-BL; CAVICAVENMI | before surgery; the second visit post intervention |
| 3 | Park et al. (13) | Prospective longitudinal | 245 | 66.7 | EORTC QLQ-C30; NMIBC24 | Pre-Op; 3 months post TURBT; 6 months post TURBT |
| 4 | Siracusano et al. (14) | Prospective longitudinal | 103 | – | EORTC (QLQ-C30 and QLQ-BLS24) | Start of instillation; last instillation; 3 months post instillation |
| 5 | Schmidt et al. (15) | Prospective cohort | 244 | 69 | SF-36, BCI | Baseline; 6 months post follow up; 12 months post follow up |
| 6 | Brisbane et al. (16) | Survey | 325 | – | SF-36, VR-12 | Baseline; post diagnosis |
| 7 | Yokozimo et al. (17) | RCT | 171 | 68 | EORCT QLQ-C30; CTCAE version 3.0 | Baseline; within 2 weeks of completion/discontinuation of BCG therapy |
| 8 | Mack et al. (18) | Prospective | 85 | 59 | Author designed questionnaire | Start of intravesical therapy, twice more during maintenance |
| 9 | Abbona et al. (19) | Cross sectional | 63 | 67 | Author designed questionnaire | 12 months after first cycle of intravesical therapy |
| 10 | Bhole et al. (20) | Prospective, cohort | 30 | 67 | Münchner Lebensqualitäts-Dimensionen-Liste (MLDL) | After TURBT; after intravesical therapy; 3 months follow up |
| 11 | Allareddy et al. (21) | Cross-sectional, mailed | 177 | 73.3 | Fact-BL; FACT G | After treatment |
| 12 | Gilbert et al. (22) | Cross sectional, mailed | 127 | Median 69 | BCI | After treatment |
| 13 | Gontero et al. (23) | RCT | 88 | 67.4 | EORTC QLQ-30, QLQ-BLS24 | Baseline; before induction; after maintenance |
| 14 | Koga et al. (24) | RCT | 51 | 20–79 | EORTC QLQ-C30 | Baseline; after 5th induction; 4 weeks after induction; 14 months after randomization |
| 15 | Kowalkoski et al. (25) | Mixed-methods: cross-sectional, quantitative telephone, survey, semi structured, qualitative interviews | Quantitative, 117 | 64.6 | EORTC QLQ-BLS24 | After treatment |
| 16 | Krajewski et al. (26) | RCT | 100 | 69 | Sexual satisfaction questionnaire, HADS, NRS |
Baseline; 7 to 10 days after cystoscopy |
| 17 | Sighinolfi et al. (27) | Prospective longitudinal | 30 | 69.9 | SF-36, BCI | Third or 4th session of treatment |
| 18 | Singer et al. (28) | Cross sectional | 210 | 67 | EORTC-QLQ | 30–40 days after last treatment |
| 19 | van der Aa et al. (29) | Cross sectional | 142 | 65 | VAS, EORTC-QLQ-BLS24 | The start of surveillance; <3 months after the diagnosis of primary or recurrent NMIBC |
| 20 | Yoshimura et al. (30) | Prospective longitudinal | 133 | 66.3 | SF-36 | Before TURBT; first TURBT; second TURBT; third TURBT; forth or more TURBT |
| 21 | Cox et al. (31) | RCT | 472 | 65.9 | EQ-5D | Baseline; 12, 24, 36-month follow up |
| 22 | Tan et al. (32) | RCT | 104 | 77 (median) | EQ-5D | Baseline; 3-month intervals for 12 months |